Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry

Hirotoshi Kikuchi, Hiroaki Miyata, Hiroyuki Konno, Kinji Kamiya, Ai Tomotaki, Mitsukazu Gotoh, Go Wakabayashi, Masaki Mori, Hirotoshi Kikuchi, Hiroaki Miyata, Hiroyuki Konno, Kinji Kamiya, Ai Tomotaki, Mitsukazu Gotoh, Go Wakabayashi, Masaki Mori

Abstract

Background: Total gastrectomy is a relatively difficult and invasive procedure among gastrointestinal surgeries, and major morbidities following total gastrectomy can be serious and fatal. This study aimed to develop and validate preoperative risk models of morbidities associated with total gastrectomy using a Japanese web-based nationwide registry.

Methods: The national clinical database was used to retrieve the records of 39,253 patients who underwent total gastrectomy in 1,841 hospitals between January 1, 2011 and December 31, 2012.

Results: Mean patient age was 69.1 years, and 73.8% of the patients were male. The overall morbidity rate was 21.5%, which included 8.1% with surgical site infection (SSI), 4.5% with anastomotic leak, 5.0% with pancreatic fistula, 3.7% with pneumonia, 1.9% with prolonged ventilation, and 1.2% with renal failure. Sex, splenectomy, and Brinkman index were selected as common risk factors for SSI, anastomotic leak, and pancreatic fistula. Pancreatectomy was the most significant preoperative risk factor in the risk model of SSI and pancreatic fistula. Need of assistance with activities of daily living, chronic obstructive pulmonary disease, previous cerebrovascular disease, American Society of Anesthesiologists score class 3 and over, presence of esophageal cancer, and body mass index more than 25 were selected as common risk factors for pneumonia, prolonged ventilation over 48 h, and renal failure.

Conclusions: We have created the first reported risk models of morbidities associated with total gastrectomy, using a Japanese nationwide database. The risk models developed in this study may be useful to preoperatively predict operative morbidities in patients undergoing total gastrectomy.

Keywords: Morbidity; Mortality; National Clinical Database; Risk model; Total gastrectomy.

Conflict of interest statement

Animal studies

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of interest

None of the authors had any potential conflicts of interest, including relevant financial interests, activities, relationships, and affiliations. This study was partially supported by a research grant from the Japanese Ministry of Health, Labour and Welfare.

Human rights statement and informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients for being included in the study.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic (ROC) curves of surgical complications (upper panels) and nonsurgical complications (lower panels) in the validation dataset consisting of 20% of the National Clinical Database (NCD) total gastrectomy population registered in 2011 and 2012. The C-index, a measure of model discrimination represented by the area under the ROC curve, was 0.635 for surgical site infection (95% CI, 0.613–0.657; p < 0.001), 0.614 for anastomotic leak (95% CI, 0.585–0.643; p < 0.001), 0.657 for pancreatic fistula (95% CI, 0.628–0.686; p < 0.001), 0.726 for pneumonia (95% CI, 0.697–0.755; p < 0.001), 0.758 for prolonged ventilation over 48 h (95% CI, 0.717–0.799; p < 0.001), and 0.795 for renal failure (95% CI, 0.749–0.841; p < 0.001)

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138.
    1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–1145. doi: 10.1002/ijc.27711.
    1. Ott K, Lordick F, Blank S, Buchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg. 2011;396(6):743–758. doi: 10.1007/s00423-010-0738-7.
    1. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 1997;226(5):613–620. doi: 10.1097/00000658-199711000-00006.
    1. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol. 2000;34(3):137–168. doi: 10.1016/S1040-8428(00)00048-2.
    1. Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg. 2013;30(2):119–129. doi: 10.1159/000350877.
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi: 10.1056/NEJMoa055531.
    1. Benhamiche AM, Faivre J, Tazi AM, Couillault C, Villing AL, Rat P. Time trends in diagnostic strategy, treatment, and prognosis of gastric cancer in the elderly: a population-based study. Eur J Cancer Prev. 1997;6(1):71–77. doi: 10.1097/00008469-199702000-00011.
    1. Fushida S, Nashimoto A, Fukushima N, Kawachi Y, Fujimura T, Kuwabara S, et al. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer. Jpn J Clin Oncol. 2012;42(2):131–133. doi: 10.1093/jjco/hyr183.
    1. Hur H, Lee HY, Lee HJ, Kim MC, Hyung WJ, Park YK, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer. 2015;15:355. doi: 10.1186/s12885-015-1365-z.
    1. Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, et al. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer. 2016
    1. Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery (St. Louis) 2014;156(2):298–304. doi: 10.1016/j.surg.2014.03.022.
    1. Watanabe M, Miyata H, Gotoh M, Baba H, Kimura W, Tomita N, et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg. 2014;260(6):1034–1039. doi: 10.1097/SLA.0000000000000781.
    1. Sauvanet A, Mariette C, Thomas P, Lozac’h P, Segol P, Tiret E, et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg. 2005;201(2):253–262. doi: 10.1016/j.jamcollsurg.2005.02.002.
    1. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27. doi: 10.1007/s10120-012-0163-4.
    1. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97–100. doi: 10.1007/s10120-011-0040-6.
    1. Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008;2(3):137–144.
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449. doi: 10.1016/S1470-2045(10)70070-X.
    1. Shiloach M, Frencher SK, Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh MG, et al. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 2010;210(1):6–16. doi: 10.1016/j.jamcollsurg.2009.09.031.
    1. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–748. doi: 10.1016/S0140-6736(95)90637-1.
    1. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–999. doi: 10.1016/S0140-6736(96)90144-0.
    1. Gluszek S, Kot M, Kuchinka J, Matykiewicz J. The influence of splenectomy performed simultaneously with gastrectomy on postoperative complications in patients with gastric cancer undergoing surgery with the intention to treat. Pol Przegl Chir. 2014;86(7):312–318.
    1. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–283. doi: 10.1097/SLA.0000000000001814.
    1. e-Stat, Portal Site of Official Statistics of Japan. 2012: . Accessed 1 Dec 2016.
    1. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92(9):1099–1102. doi: 10.1002/bjs.4952.
    1. Takama T, Okano K, Kondo A, Akamoto S, Fujiwara M, Usuki H, et al. Predictors of postoperative complications in elderly and oldest old patients with gastric cancer. Gastric Cancer. 2015;18(3):653–661. doi: 10.1007/s10120-014-0387-6.
    1. Lee KG, Lee HJ, Yang JY, Oh SY, Bard S, Suh YS, et al. Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien–Dindo system. J Gastrointest Surg. 2014;18(7):1269–1277. doi: 10.1007/s11605-014-2525-1.

Source: PubMed

3
Sottoscrivi